Deeptech factory
LUMEDIX
Next-generation in vitro diagnostics
LumediX has developed a technology to increase the sensitivity of in vitro diagnostic tests by a factor of 100 to 1000.
CEO: Maximilian Richly
Creation: july 2018
Headcount: 11
TECHNO / PRODUCTS
Lumedix technology is based on luminescent rare-earth-based nanoparticles, which can suit to any type of immunoassay and lower the
minimum detectable concentration of any type of immunoassay by several orders of magnitude.
PRODUCTS PORTFOLIO
- Feasibility studies
- Licensing of luminescent nanoparticles
- Diagnostic tests proprietary
APPLICATIONS
LumediX initially applies its technology in the field of rapid diagnostics tests (“Point-of-Care”, “Point-of-Use”), giving them analytical sensitivities equivalent to tests performed today in analytical laboratories.
BENEFITS
Lumedix nanoparticles, acting as detection probes, produce a higher signal-to-noise ratio than conventional probes, thanks to their unique physicochemical properties, hence producing a test with superior analytical sensitivity than current marketed probes.
LUMEDIX MINUTE
